02841 Global X China MedTech ETF
- 35.940
- +1.340+3.87%
The gross margin of injection products in the solution category has declined, and the imeik technology development's Q2 performance growth rate has dropped to single digits| Speed reading announcement.
①Imeik Technology Development's H1 revenue and net income growth rate slowed down. ②The gross margin of solution injection products has declined, and its proportion in total revenue has further decreased. ③In addition to laying out research and development pipelines for botulinum toxin, GLP-1 drugs, the company is also further expanding in the medical beauty equipment field.
Annual Financial Report
FINANCIAL STATEMENTS
How long can the American customer love myth of high growth last? | Insight Research
Despite 3 consecutive years of high performance growth, market concerns about Aimeike's future growth momentum have not been resolved.
Is the healthcare market recovering? Mindray Healthcare acquires control of Whitney Healthcare at 25% premium | Insight Research
In the new year, A was born, and the leading device company Mindray entered the cardiovascular field at a premium.
Behind the slowdown in Aimeike's growth rate in the 3rd quarter: “Women's Maotai” can't handle the slump in consumption?
Demand weakens
“Ate” 19 hospitals in one go, and Aier Ophthalmology went to the county
Aier Ophthalmology is already a “veteran” of industrial fund mergers and acquisitions. On September 21, Aier Ophthalmology announced that it plans to spend 860 million yuan to acquire some shares in a total of 19 ophthalmology hospitals, including Hainan Air and Zaozhuang Aier, held by 6 industrial investment funds. According to statistics from TradeWind01 (ID: TradeWind01), the total revenue of these 19 hospitals in 2022 and January to July 2023 could reach 523 million yuan and 379 million yuan respectively. Judging from the geographical location of the merger and acquisition targets, a total of 6 ophthalmology hospitals including Hanchuan Aier are located in county-level cities, and a total of 3 ophthalmology hospitals including Yuanling Aier
Medical beauty earns 200 million dollars a month and has to participate in the internal volume of diet pills. Where is the boundary of America's ambition?
It's not easy to take diet pills
2023 Interim Report | When CT Is No Longer a “Amulet”: What is Lianying Healthcare's MR Growth Space
Also watch This Morning
The periphery of the Asia-Pacific region generally fell, Hong Kong stocks plummeted, and the Hang Seng Index hit a new low of more than a month. What are the risks?
A sharp drop of over 600 points.
Before the Bell | Nasdaq In Line for Fresh 9-month High Amid Hopes Fed Rate Hikes Are At an End
What to Expect in the Week Ahead (DIS, JD, LI and RBLX Earnings; Inflation Data, Debt Ceiling)
Alibaba Up 2%, Nio Down 4%: Hong Kong Stocks Mixed as Investors Brace for Fed Minutes, JOLTS Data
Alibaba, Nio Slip: Hang Seng Marks Weak Start to 2023 After Gloomy China Factory Activity Data
Alibaba, Nio Down Nearly 1%: Hang Seng Mirrors Wall Street Weakness Amid Red-Hot Japan Inflation
Alibaba, Nio Soar: Hang Seng Jumps Over 2% as Wall Street Cheers Upbeat Consumer Confidence Reading
Alibaba, Nio Rise: Hang Seng Rises On Wall Street Cues, City Chief John Lee Gears Up for Beijing Visit
Alibaba, Nio Drop Over 2%: Hang Seng Opens Weaker as Wall Street 'Santa Claus' Rally Remains Elusive
Alibaba Up 3%, Nio Down 2%: Hang Seng Opens Higher as China Economic Optimism Outweighs
Alibaba, JD, Tech Peers Fall: Hang Seng Opens Lower On Weak Wall Street Cues as Recession Fears Grow